Renaissance Technologies
PMCB icon

Renaissance Technologies’s PharmaCyte Biotech PMCB Stock Holding History

Renaissance Technologies’s Portfolio PMCB Stock Details PMCB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$26.6K Buy
3,407
+1,408
+70% +$14.7K ﹤0.01% 3115
2026
Q2 		$29.2K Sell
1,999
-975
-33% -$13.9K ﹤0.01% 3076
2026
Q1 		$37.6K Sell
2,974
-1,975
-40% -$28.7K ﹤0.01% 3127
2025
Q4 		$68.1K Buy
4,949
+738
+18% +$12.6K ﹤0.01% 3059
2025
Q3 		$77.6K Buy
4,211
+1,590
+61% +$30.1K ﹤0.01% 3289
2025
Q2 		$54.3K Buy
2,621
+16
+0.6% +$339 ﹤0.01% 3383
2025
Q1 		$61.9K Buy
2,605
+10
+0.4% +$308 ﹤0.01% 3268
2024
Q4 		$77.4K Sell
2,595
-21
-0.8% -$689 ﹤0.01% 3320
2024
Q3 		$94.9K Buy
2,616
+63
+2% +$2.23K ﹤0.01% 3266
2024
Q2 		$95.1K Buy
2,553
+248
+11% +$10.1K ﹤0.01% 3192
2024
Q1 		$104K Buy
2,305
+300
+15% +$12.3K ﹤0.01% 3360
2023
Q4 		$82K Buy
2,005
+273
+16% +$11.2K ﹤0.01% 3353
2023
Q3 		$69K Buy
1,732
+370
+27% +$17.9K ﹤0.01% 3330
2023
Q2 		$74K Buy
+1,362
New +$77.6K ﹤0.01% 3535

Other funds holding PMCB

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Jane Street
Jane Street New York $1.19T AUM 51.51% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
StoneX Group
StoneX Group New York $2.75B AUM 24.13% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM
Equitec Proprietary Markets
Equitec Proprietary Markets Chicago, Illinois $400M AUM 66.98% 1-Year Est. Return
GSC
Ground Swell Capital Folly Beach, South Carolina $43.4M AUM 20.78% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $77B AUM 19.24% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $83.6B AUM 19.78% 1-Year Est. Return
Keating Financial Advisory Services
Keating Financial Advisory Services Manhattan, Kansas $775M AUM 22.27% 1-Year Est. Return

Renaissance Technologies's PMCB Position: Q3 2026 in Review

Renaissance Technologies increased its PharmaCyte Biotech (PMCB) stake by 70% in Q3 2026, buying an estimated $14.7K and bringing the position to 3,407 shares worth $26.6K. The position accounts for ﹤0.01% of the portfolio, ranked #3115.

Renaissance Technologies first reported a position in PMCB in Q2 2023 and has held it in 14 quarters since. The position peaked at $104K in Q1 2024. 13 funds tracked by Wall St. Rank hold PMCB as of Q3 2026.

  • Renaissance Technologies held 3,407 shares of PharmaCyte Biotech worth $26.6K as of Q3 2026.
  • Renaissance Technologies bought 1,408 PharmaCyte Biotech shares in Q3 2026, an estimated $14.7K.
  • PharmaCyte Biotech made up ﹤0.01% of Renaissance Technologies's portfolio in Q3 2026, its #3115 holding.
  • Renaissance Technologies first reported a position in PharmaCyte Biotech in Q2 2023 and has held it in 14 quarters since.
  • Renaissance Technologies's PharmaCyte Biotech position peaked at $104K in Q1 2024.
  • 13 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q3 2026.

Based on Renaissance Technologies's 13F filing for Q3 2026, filed 12 Nov 2026.